Maryland regulators slash BGE rate request, citing affordability concerns

Maryland regulators approved $77.2 million of Baltimore Gas and Electric’s $152.3 million 2023 true-up request, citing affordability concerns and budget overruns after finding BGE exceeded approved program budgets and spent $323 million of additional capital above authorized levels. The commission limited recovery and stretched allowed costs to reduce immediate bill impacts—raising average residential electric bills about $0.72/month and gas bills about $1.95/month starting February 2026 through end-2027—and noted recent state legislation banning future true-ups and establishing a Legislative Relief Fund. The decision, influenced by extensive public input and scrutiny from the Maryland People’s Counsel, constrains near-term revenue recovery for BGE/parent Exelon and signals tougher regulatory oversight of utility multiyear rate plans.

Analysis

Market structure: The PSC’s denial (~$75M of $152M requested) is a narrowly material cash-recovery hit to BGE/Exelon but a large regulatory signal: regulators will prioritize affordability over cost pass-through. Near term this trims BGE’s allowed short-term cash flow and investor visibility, but the order extends amortization which mutes monthly customer impact; expect rating agencies to watch for sustained disallowances rather than one-off amounts.

Risk assessment: Tail risks include broader successful legislative bans on true-ups (already signaled) or repeat disallowances across other state jurisdictions, which could force utilities to defer ~$200M+ regional capex and raise outage/risk of fines — low probability but high impact. Immediate market reaction (days-weeks) will be driven by sentiment; over 6–18 months the bigger risk is precedent that compresses regulated ROE and forces higher equity raises or more parent support (Exelon already provided $50M community funds).

Trade implications: Direct trade: EXC equity is vulnerable to multiple compressions and regulatory repricing — prefer option hedges or modest short exposure vs outright long. Cross-asset: EXC corporate spreads could widen; buy protection if 3–6 month spreads widen >30–50bp. Rotate from capex-heavy regulated utilities toward regulated names with firmer allowed ROE (e.g., NEE/DUK) and short EXC vs those peers in a 3–9 month pair trade.

Contrarian angle: Consensus may overstate the earnings hit — $75M is <1% of Exelon consolidated revenue and the amortization extension reduces immediate EPS volatility (likely < $0.05–$0.10/share annualized). If markets overreact, there’s a tactical opportunity to buy downside protection-funded call spreads after clarity (30–90 days) if no further regulatory disallowances materialize.

Key Decisions for Investors

• Establish a 2–3% short position in EXC equities (or equivalent inverse exposure) within 5 trading days; set a disciplined stop-loss at +8% and a profit target of 18–25% within 3–9 months if regulatory headwinds persist.
• Buy a 4–6 month EXC put spread (buy 1x 5% OTM put, sell 1x 12–15% OTM put) to cap premium outlay while targeting downside from regulatory repricing; size to cost ~0.5–1% portfolio risk.
• Initiate a 1–3% long allocation to higher-quality regulated names (e.g., NEE, DUK) and short EXC in equal notional amounts as a pair trade to capture relative regulatory stability over 3–12 months.
• Purchase 3–5 year credit protection (CDS or bond hedges) on EXC/BGE if corporate spreads widen >30–50bp from current levels; if spreads widen that much, raise hedge to 5% portfolio notional until regulatory clarity.
• Monitor three catalysts in the next 30–90 days and act: (1) Maryland PSC filings for appeals or rehearing (if Exelon asks for rehearing, increase short/put exposure by 50%), (2) Exelon Q4/2025 guidance and any capex deferral >$200M (trim longs by 25%), and (3) any federal/state legislative moves codifying true-up prohibitions (if passed, increase short EXC exposure).